Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | PRMT1 | Q99873 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DDIT3 | P35638 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 9/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13744285 | 0.89 | BUB1 (0.40) | KMT2AMEN1BCL2MAPTTP53 | |
| SCHEMBL4245920 | 0.88 | MEN1 (0.43) | KMT2AMEN1HPGDLMNAMAPT | |
| SCHEMBL4238703 | 0.87 | NPC1 (0.41) | KMT2AMEN1HPGDKDM4EMAPT | |
| SCHEMBL13743546 | 0.86 | KMT2A (0.44) | KMT2AMEN1HPGDBCL2PRMT1 | |
| SCHEMBL4249844 | 0.84 | SMN1; SMN2 (0.46) | KMT2AMEN1HPGDLMNAMAPT | |
| SCHEMBL13743523 | 0.83 | SMN1; SMN2 (0.47) | KMT2AMEN1LMNAMAPT | |
| SCHEMBL4246935 | 0.83 | NPC1 (0.47) | KMT2AMEN1MAPTTP53 | |
| SCHEMBL4244834 | 0.83 | NPC1 (0.51) | KMT2AMEN1KDM4ELMNAMAPT | |
| SCHEMBL4544143 | 0.82 | NR0B1 (0.51) | KMT2AMEN1HPGDBCL2PRMT1 | |
| SCHEMBL4245974 | 0.82 | DEGS1 (0.46) | HPGDNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | HURLEY TIMOTHY BRIAN | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203694-A1 | INHIBITORS OF UNDECAPRENYL PYROPHOSPHATE SYNTHASE | FDPS, UMPS, GGPS1 | KMT2A 4780/4885MEN1 2345/4885HPGD 158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.